MedTrace Logo

Evaluation of the Ergogenic Properties of Hesperetin on Exercise-induced Fatigue

NCT07104734 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-08-05

No results posted yet for this study

Summary

Twenty young, healthy, physically active men and women (12\~30 years) did a pre-post trial randomized into placebo or HST trials (500 mg/d for two weeks). HST supplementation enhanced endurance judo-specific performance and effectively attenuated exercise-induced fatigue, oxidative stress, inflammatory response, and muscle damage.

Conditions

  • Healthy
  • Athletes

Interventions

OTHER

Placebo (Placebo trial)

The Placebo capsule supplement was taken for 2 weeks (2 capsules per day)

OTHER

Hesperetin (Hesperetin trial)

The Hesperetin capsule supplement was taken for 2 weeks, with a daily dosage of 500 mg of Hesperetin (equivalent to 2 capsules per day, each containing 250 mg of Hesperetin and 50 mg Pycnogenol®).

Sponsors & Collaborators

  • China Medical University, Taiwan

    collaborator OTHER

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Jung-Piao Tsao · China Medical University, China

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-03
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07104734 on ClinicalTrials.gov